News

• Vincobiosis® Acneic harnesses the full potential of plants through plant biotechnology, transforming it into Canonia Allysis®, a unique ingredient that regulates skin microbiota balance.
• This new range is being introduced in Spain through the company’s specialized commercial network and will subsequently expand into other European markets via its subsidiaries and internationally through licensing and distribution agreements.

REIG JOFRE, (BME:RJF), a pharmaceutical company listed on the Spanish Stock Exchange, reinforces its dermatology business with the launch of Vincobiosis® Acneic, an innovative range of topical products that blend science and nature to effectively and gently manage acne-prone skin.

This new product line has been designed and developed by REIG JOFRE’s innovation team and is based on Canonia Allysis®, a unique plant-based biotechnology ingredient obtained through an advanced and sustainable process, developed using technology from Vytrus Biotech, a biotech company listed on BME Growth (BME: VYT). This active ingredient blends biotechnology with nature by selecting natural defense mechanisms used by certain plants to protect themselves from bacterial infections and environmental threats, thereby intelligently restoring the balance of the skin’s microbiota, without harming microorganisms essential to skin health.

Clinical studies have shown that Vincobiosis® Acneic naturally reduces imperfections in acne-prone skin without disrupting the skin ecosystem, removing beneficial microorganisms, or causing damage.

The topical range consists of three products formulated to address the specific needs of acne-prone skin.

Initially launched in Spain through REIG JOFRE’s specialized network of medical and pharmaceutical representatives, the product line will subsequently be introduced in other European markets through REIG JOFRE subsidiaries located in Spain, France, Belgium, Sweden, and Poland. Internationally, it will be marketed through licensing and distribution agreements with commercial partners.

“With Vincobiosis® Acneic, we reaffirm our commitment to innovation in dermatology and collaboration within the health ecosystem. Our goal is to develop differentiated technological platforms that offer new concepts in skincare through advanced solutions for patients”, stated Ignasi Biosca, CEO of REIG JOFRE.

This development is part of REIG JOFRE’s dermatology growth strategy, reinforcing its market position and broadening its impact on skincare. Vincobiosis® Acneic joins CicloTech®, the company’s patented trans-ungual delivery technology for nail care, leading to successful products such as DexULac® for onychomycosis and RegeNail®, a topical solution for structural and aesthetic nail alterations.

For more information about Vincobiosis® Acneic, visit: vincobiosis.com.